focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Share News (SYNC)

Share Price Information for Syncona (SYNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 112.20
Bid: 112.00
Ask: 113.00
Change: -2.60 (-2.26%)
Spread: 1.00 (0.893%)
Open: 114.00
High: 114.20
Low: 112.20
Prev. Close: 114.80
SYNC Live PriceLast checked at -
Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Omicron hope lifts FTSE despite UK virus surge

Wed, 22nd Dec 2021 17:03

(Alliance News) - Equity prices in London on Wednesday shook off news of fresh daily record coronavirus infections in the UK to end higher amid cautious optimism over the severity of the Omicron variant.

The FTSE 100 index closed up 44.25 points, or 0.6%, at 7,341.66. The FTSE 250 ended up 260.49 points, or 1.1%, at 23,080.79, and the AIM All-Share closed up 10.24 points, or 0.9%, at 1,183.81.

The Cboe UK 100 ended up 0.5% at 726.92, the Cboe UK 250 closed up 1.3% at 20478.57, and the Cboe Small Companies ended up 1.2% at 15004.11.

In European equities on Wednesday, the CAC 40 in Paris ended up 1.1% and the DAX 40 in Frankfurt ended up 1.0%.

Tentative optimism over the Omicron coronavirus variant supported markets on Wednesday.

"Some preliminary results from the UK Health & Security agency around the effects of the Omicron variant appear to be being received positively today. In line with South Africa's experience, it would appear that the Omicron variant does indeed appear to be milder, although the report also suggests that the higher infection rate could also place increased strain on hospitals, if enough people get it even if mortality is lower," said Michael Hewson, chief market analyst at CMC Markets.

"Nonetheless, it is still good news, and helps justify the move to delay a decision on new restrictions in England until after Christmas, and potentially allow greater leeway next week when restrictions could well change again."

UK Prime Minister Boris Johnson on Tuesday gave the go-ahead for people's Christmas plans, although he warned tougher restrictions could be implemented post-December 25.

However, Wales on Wednesday followed Scotland in unveiling new post-Christmas coronavirus curbs, primarily around hospitality and large events, as the UK's devolved nations move at different speeds to surging Omicron variant cases.

This came as the UK clocked another daily new cases record – 106,122 – as it announced it would buy millions of Covid pills, and also cut the isolation period for infected people from 10 to seven days with negative tests.

Sterling strengthened, however. The pound was quoted at USD1.3346 at the London equities close Wednesday, jumping from USD1.3248 at the close on Tuesday after some mixed gross domestic product data.

On the quarter before, UK gross domestic product advanced by 1.1% in the three months to September, slower than a 5.4% rise in the three months to July and missing consensus of an expansion of 1.3%, which would have matched the first estimate. On a year before, the UK economy grew by 6.8% in the third quarter, slightly beating the market forecast of 6.6% annual growth, which also would have matched the first estimate.

The ONS said the largest contributors to the increase in GDP were hospitality and arts, entertainment & recreation, following the further easing of restrictions and reopening of the economy during the period - something which could now be at risk given the Omicron wave.

Other countries have started to impose restrictions to curb the virus's spread. The Netherlands has already imposed a Christmas lockdown and Germany has slapped a limit of 10 people on private parties, closed nightclubs and banned spectators from major events including soccer matches.

Shaking this off, London-listed travel and leisure firms gained on Wednesday. Jet engine maker Rolls-Royce ended up 3.3% and Holiday Inn owner InterContinental Hotels Group rose 2.7%.

Pandemic-battered stocks also ended in the green in the mid-cap FTSE 250 index, with food and beverage outlets operator SSP Group rising 4.8% and Mitchells & Butlers up 2.7%.

Elsewhere, Taylor Wimpey rose 2.2% after committing to removing terms from contracts that double ground rents for leaseholders every 10 years.

Taylor Wimpey said the UK Competition & Markets Authority investigation into the historical sale of leasehold properties with doubling ground rent clauses by the company is closed, following the agreement of voluntary undertakings. The High Wycombe-based housebuilder said the cost of the undertakings falls within the original provision Taylor Wimpey made in 2017.

Syncona jumped 5.5% after the healthcare investor said its portfolio company Gyroscope Therapeutics will be sold to Swiss pharmaceutical maker Novartis for up to USD1.5 billion.

Syncona has a 54% stake in Gyroscope following a USD42 million investment in March, after co-founding the business in 2016. In a bumper payday, Syncona will receive upfront cash proceeds of GBP334 million from the deal, representing a GBP180 million uplift to the current holding value.

Stocks in New York were higher at the London equities close, with the DJIA up 0.5%, the S&P 500 index up 0.7%, and the Nasdaq Composite up 0.9%.

The dollar was on the back foot amid Wednesday's cautious optimism, failing to get a boost from an upwards revision to the US economy's performance in the third quarter.

On an annual basis, the US economy grew at a rate of 2.3% in the three months to September, slowing from a 6.7% expansion in the second quarter. The latest reading beat the market forecast of an expansion of 2.1%, however, which would have matched the second estimate.

The euro stood at USD1.1327 at the European equities close Wednesday, up against USD1.1267 at the same time on Tuesday.

Gold benefited from dollar weakness. The shining metal was quoted at USD1,797.90 an ounce at the London equities close Wednesday, rising from USD1,785.40 at the close on Tuesday.

However, the safe haven Japanese yen eased back. Against the yen, the dollar rose to JPY114.22 compared to JPY114.14 late Tuesday.

Brent oil was quoted at USD74.74 a barrel at the London equities close Wednesday, up from USD73.48 late Tuesday.

Thursday's economic calendar has German import prices at 0700 GMT and US initial jobless claims at 1330 GMT, alongside durable goods orders and core personal consumption expenditures due at the same time.

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
17 May 2024 14:34

Syncona notes Autolus's first quarter loss widens amid higher costs

(Alliance News) - Syncona Ltd on Friday noted that Autolus Therapeutics PLC reported an increased loss amid higher operating costs.

Read more
9 May 2024 13:58

IN BRIEF: Syncona's Freeline gets positive results for Gaucher disease

Syncona Ltd on Thursday - London-based investor in healthcare companies - Says UK portfolio company Freeline Therapeutics Ltd presents positive new data from its phase I and II Galileo-1 study of FLT201, its novel gene therapy candidate, in Gaucher disease. Says FLT201 demonstrates a favourable safety and tolerability profile, with no infusion reactions and no severe adverse events. Syncona notes that Gaucher disease is a "debilitating genetic disorder caused by a deficiency of the GCase enzyme". Syncona Chief Executive Officer Chris Hollowood says: "We are very encouraged by the data generated from FLT201 which demonstrates a favourable safety and tolerability profile and significant enzyme activity. We are confident this treatment has the potential to challenge the standard of care in Gaucher disease, where current treatments are life-long and do not fully alleviate the disease." Freeline Therapeutics is based in Stevenage, Hertfordshire.

Read more
9 May 2024 11:19

Syncona reports positive findings from investee Freeline

(Sharecast News) - Life science investor Syncona reported positive findings from its portfolio company Freeline Therapeutics on Thursday, after a phase one and two study of its gene therapy candidate for Gaucher disease, 'FLT20', showed encouraging results.

Read more
3 May 2024 09:14

LONDON BROKER RATINGS: Jefferies cuts AJ Bell; Deutsche likes ConvaTec

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

Read more
11 Apr 2024 14:22

Syncona agrees to sell stake in investee company for GBP7.4 million

(Alliance News) - Syncona Ltd on Thursday said it has reached an agreement to sell one of its portfolio companies to US biotechnology firm, Century Therapeutics Inc.

Read more
4 Apr 2024 17:06

IN BRIEF: Syncona notes investee Achilles's annual loss narrows

Syncona Ltd - London-based investor in healthcare companies - Notes that the loss of investee and clinical-stage biopharmaceutical company Achilles Therapeutics PLC narrows by 2.7% to USD68.2 million in 2023 from USD71.1 million in 2022. General and administrative costs contract by 19% to USD17.0 million from USD21.1 million. According to Syncona's website, the company has a 25% stake in Achilles.

Read more
14 Mar 2024 14:16

Syncona portfolio company Autolus posts widened loss for 2023

(Alliance News) - Syncona Ltd on Thursday noted the 2023 results of one of its life science portfolio companies, which showed a widened loss and an increase in annual expenses.

Read more
12 Feb 2024 18:01

IN BRIEF: Freeline shareholders approve Syncona acquisition

Syncona Ltd - London-based investor in healthcare companies - Freeline Therapeutics Holdings PLC shareholders approve acquisition by Syncona.

Read more
8 Feb 2024 13:45

UPDATE: Syncona portfolio strengthens thanks to Autolus

(Alliance News) - Syncona Ltd on Thursday said its portfolio company Autolus Therapeutics PLC has struck a deal to work with BioNTech to commercialise its CAR-T programmes.

Read more
8 Feb 2024 09:41

Syncona portfolio strengthens in third quarter thanks to Autolus

(Alliance News) - Syncona Ltd on Thursday reported a recent increase to the value of its portfolio, as the company said it was in a strong position to push forward its main life science companies.

Read more
8 Feb 2024 09:04

Syncona NAV grows in Q3

(Sharecast News) - Life sciences investor Syncona said on Thursday that its net asset value had grown in the three months ended 31 December, driven by a prioritisation of capital allocation across its portfolio to enable the delivery of key inflection points.

Read more
22 Jan 2024 12:19

IN BRIEF: Syncona notes FDA acceptance of Autolus's BLA for obe-cel

Syncona Ltd - London-based investor in healthcare companies - The US Food & Drug Administration accepts Autolus Therapeutics PLC's biologics licence application for obe-cel for patients with relapsed/refractory adult B-cell acute lymphoblastic leukaemia. The FDA has set a target action date of November 16 for reviewing the application, Syncona says. Further, Autolus is on track to submit a marketing authorisation application to the EU's European Medicines Agency in the first half of 2024.

Read more
19 Jan 2024 08:36

Syncona says Freeline trial for Gaucher disease treatment positive

(Alliance News) - Syncona Ltd on Friday noted Freeline Therapeutics Holdings PLC's positive data for Gaucher disease treatment.

Read more
4 Dec 2023 09:37

IN BRIEF: Syncona notes Beacon's "encouraging" AGTC-501 trial data

Syncona Ltd - London-based investor in healthcare companies - Says portfolio company, Beacon Therapeutics has presented three-month data from the phase 2 Skyline trial of its viral vector-based gene therapy AGTC-501 in X-linked retinitis pigmentosa at the Floretina ICOOR 2023 Congress in Rome. Notes AGTC-501 shows an "encouraging efficacy profile", showing a "significant improvement" in retinal sensitivity. Adds that there are no clinically significant safety events related to AGTC-501.

Read more
27 Nov 2023 19:03

TRADING UPDATES: Molten Ventures completes raise; Saietta proposes one

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.